Europe
Multiple pharma company stocks make their first appearance on the Nasdaq this morning to advance the next-generation therapeutics. BioSpace takes a look at some of these IPOs.
Roche had a big week, scoring wins but also stepping away from its gene therapy partnership with 4D Molecular Therapeutics.
A new class of compounds currently in development against acute myeloid leukemia has been discovered to block coronavirus reproduction in human lung cells.
German biotechnology firm LEUKOCARE, which has operations in Milford, Connecticut, has announced the closing of $17.5 million financing round from New York investment firm Petrichor Healthcare Capital Management.
The analysis showed that the Pfizer and Oxford/AstraZeneca vaccines can protect patients from being hospitalized by as much as 90 percent.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Concerns over vaccination links to heart inflammation are valid, a U.S. Centers for Disease Control and Prevention advisory committee announced this afternoon.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
uniQure has acquired Corlieve with upfront cash of approx. $55 million and will center on the latter’s lead program, AMT-260, an advanced treatment for TLE.
CEO Emma Walmsley’s vision includes a projected $46 billion in annual sales from the stand-alone pharma company by 2031 and more than 10% operating profit over the next five years.
PRESS RELEASES